Retinal toxic effects associated with intravitreal fomivirsen

Archives of Ophthalmology

Volumn 118, Issue 3, 2000, Pages 426-427

  Amin, Haris I ^a   Ai, Everett ^b   McDonald, H Richard ^b   Johnson, Robert N ^b  

^a Northern Illinois Retina Ltd   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FOMIVIRSEN; GANCICLOVIR; STEROID;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; EYE INFLAMMATION; EYE TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NIGHT BLINDNESS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DISEASE; SCOTOMA; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; GANCICLOVIR; HIV INFECTIONS; HUMANS; INJECTIONS; MALE; NIGHT BLINDNESS; RETINA; RETINAL DISEASES; THIONUCLEOTIDES; VISUAL ACUITY; VISUAL FIELDS; VITREOUS BODY;

EID: 0034062551     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Amin HI, Ai E. Current management of CMV retinitis. Ophthalmic Pract. 1998;16:244-249.
2. Marwick C. First "antisense" drug will treat CMV retinitis. JAMA. 1998;280:871.